The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: A retrospective study

Alexandra W. Elias, Pashtoon M. Kasi, John A. Stauffer, David D. Thiel, Dorin T. Colibaseanu, Kabir Mody, Richard W Joseph, Sanjay P. Bagaria

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICI) are revolutionizing care for cancer patients. The list of malignancies for which the Food and Drug Administration is granting approval is rapidly increasing. Furthermore, there is a concomitant increase in clinical trials incorporating ICI. However, the safety of ICI in patients undergoing surgery remains unclear. Herein, we assessed the safety of ICI in the perioperative setting at a single center. We conducted a retrospective review of patients who underwent planned surgery while receiving ICI in the perioperative setting from 2012 to 2016. We collected 30-day postoperative morbidity and mortality utilizing the Clavien-Dindo classification system. We identified 17 patients who received perioperative ICI in 22 operations. Patients were diagnosed with melanoma (n = 14), renal cell carcinoma (n = 2), and urothelial carcinoma (n = 1). Therapies included pembrolizumab (n = 10), ipilimumab (n = 5), atezolizumab (n = 5), and ipilimumab/nivolumab (n = 2). Procedures included cutaneous/subcutaneous resection (n = 6), lymph node resection (n = 5), small bowel resection (n = 5), abdominal wall resection (n = 3), other abdominal surgery (n = 3), orthopedic surgery (n = 1), hepatic resection (n = 1), and neurosurgery (n = 2). There were no Grade III-IV Clavien-Dindo complications. There was one death secondary to ventricular fibrillation in the setting of coronary artery disease. ICI appear safe in the perioperative setting, involving multiple different types of surgery, and likely do not need to be stopped in the perioperative setting. Further studies are warranted to confirm these findings.

Original languageEnglish (US)
Article number121
JournalFrontiers in Oncology
Volume7
Issue numberJUN
DOIs
StatePublished - Jun 12 2017

Fingerprint

Retrospective Studies
Safety
Neurosurgery
Abdominal Wall
Ventricular Fibrillation
United States Food and Drug Administration
Renal Cell Carcinoma
Orthopedics
Coronary Artery Disease
Melanoma
Neoplasms
Patient Care
Lymph Nodes
Clinical Trials
Morbidity
Carcinoma
Skin
Mortality
Liver
ipilimumab

Keywords

  • Cancer
  • Immune checkpoint inhibitors
  • Morbidity
  • Serious adverse events
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Elias, A. W., Kasi, P. M., Stauffer, J. A., Thiel, D. D., Colibaseanu, D. T., Mody, K., ... Bagaria, S. P. (2017). The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: A retrospective study. Frontiers in Oncology, 7(JUN), [121]. https://doi.org/10.3389/fonc.2017.00121

The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors : A retrospective study. / Elias, Alexandra W.; Kasi, Pashtoon M.; Stauffer, John A.; Thiel, David D.; Colibaseanu, Dorin T.; Mody, Kabir; Joseph, Richard W; Bagaria, Sanjay P.

In: Frontiers in Oncology, Vol. 7, No. JUN, 121, 12.06.2017.

Research output: Contribution to journalArticle

Elias, Alexandra W. ; Kasi, Pashtoon M. ; Stauffer, John A. ; Thiel, David D. ; Colibaseanu, Dorin T. ; Mody, Kabir ; Joseph, Richard W ; Bagaria, Sanjay P. / The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors : A retrospective study. In: Frontiers in Oncology. 2017 ; Vol. 7, No. JUN.
@article{c95198cabbc34cd9b8ef2988fcabf85d,
title = "The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: A retrospective study",
abstract = "Immune checkpoint inhibitors (ICI) are revolutionizing care for cancer patients. The list of malignancies for which the Food and Drug Administration is granting approval is rapidly increasing. Furthermore, there is a concomitant increase in clinical trials incorporating ICI. However, the safety of ICI in patients undergoing surgery remains unclear. Herein, we assessed the safety of ICI in the perioperative setting at a single center. We conducted a retrospective review of patients who underwent planned surgery while receiving ICI in the perioperative setting from 2012 to 2016. We collected 30-day postoperative morbidity and mortality utilizing the Clavien-Dindo classification system. We identified 17 patients who received perioperative ICI in 22 operations. Patients were diagnosed with melanoma (n = 14), renal cell carcinoma (n = 2), and urothelial carcinoma (n = 1). Therapies included pembrolizumab (n = 10), ipilimumab (n = 5), atezolizumab (n = 5), and ipilimumab/nivolumab (n = 2). Procedures included cutaneous/subcutaneous resection (n = 6), lymph node resection (n = 5), small bowel resection (n = 5), abdominal wall resection (n = 3), other abdominal surgery (n = 3), orthopedic surgery (n = 1), hepatic resection (n = 1), and neurosurgery (n = 2). There were no Grade III-IV Clavien-Dindo complications. There was one death secondary to ventricular fibrillation in the setting of coronary artery disease. ICI appear safe in the perioperative setting, involving multiple different types of surgery, and likely do not need to be stopped in the perioperative setting. Further studies are warranted to confirm these findings.",
keywords = "Cancer, Immune checkpoint inhibitors, Morbidity, Serious adverse events, Surgery",
author = "Elias, {Alexandra W.} and Kasi, {Pashtoon M.} and Stauffer, {John A.} and Thiel, {David D.} and Colibaseanu, {Dorin T.} and Kabir Mody and Joseph, {Richard W} and Bagaria, {Sanjay P.}",
year = "2017",
month = "6",
day = "12",
doi = "10.3389/fonc.2017.00121",
language = "English (US)",
volume = "7",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors

T2 - A retrospective study

AU - Elias, Alexandra W.

AU - Kasi, Pashtoon M.

AU - Stauffer, John A.

AU - Thiel, David D.

AU - Colibaseanu, Dorin T.

AU - Mody, Kabir

AU - Joseph, Richard W

AU - Bagaria, Sanjay P.

PY - 2017/6/12

Y1 - 2017/6/12

N2 - Immune checkpoint inhibitors (ICI) are revolutionizing care for cancer patients. The list of malignancies for which the Food and Drug Administration is granting approval is rapidly increasing. Furthermore, there is a concomitant increase in clinical trials incorporating ICI. However, the safety of ICI in patients undergoing surgery remains unclear. Herein, we assessed the safety of ICI in the perioperative setting at a single center. We conducted a retrospective review of patients who underwent planned surgery while receiving ICI in the perioperative setting from 2012 to 2016. We collected 30-day postoperative morbidity and mortality utilizing the Clavien-Dindo classification system. We identified 17 patients who received perioperative ICI in 22 operations. Patients were diagnosed with melanoma (n = 14), renal cell carcinoma (n = 2), and urothelial carcinoma (n = 1). Therapies included pembrolizumab (n = 10), ipilimumab (n = 5), atezolizumab (n = 5), and ipilimumab/nivolumab (n = 2). Procedures included cutaneous/subcutaneous resection (n = 6), lymph node resection (n = 5), small bowel resection (n = 5), abdominal wall resection (n = 3), other abdominal surgery (n = 3), orthopedic surgery (n = 1), hepatic resection (n = 1), and neurosurgery (n = 2). There were no Grade III-IV Clavien-Dindo complications. There was one death secondary to ventricular fibrillation in the setting of coronary artery disease. ICI appear safe in the perioperative setting, involving multiple different types of surgery, and likely do not need to be stopped in the perioperative setting. Further studies are warranted to confirm these findings.

AB - Immune checkpoint inhibitors (ICI) are revolutionizing care for cancer patients. The list of malignancies for which the Food and Drug Administration is granting approval is rapidly increasing. Furthermore, there is a concomitant increase in clinical trials incorporating ICI. However, the safety of ICI in patients undergoing surgery remains unclear. Herein, we assessed the safety of ICI in the perioperative setting at a single center. We conducted a retrospective review of patients who underwent planned surgery while receiving ICI in the perioperative setting from 2012 to 2016. We collected 30-day postoperative morbidity and mortality utilizing the Clavien-Dindo classification system. We identified 17 patients who received perioperative ICI in 22 operations. Patients were diagnosed with melanoma (n = 14), renal cell carcinoma (n = 2), and urothelial carcinoma (n = 1). Therapies included pembrolizumab (n = 10), ipilimumab (n = 5), atezolizumab (n = 5), and ipilimumab/nivolumab (n = 2). Procedures included cutaneous/subcutaneous resection (n = 6), lymph node resection (n = 5), small bowel resection (n = 5), abdominal wall resection (n = 3), other abdominal surgery (n = 3), orthopedic surgery (n = 1), hepatic resection (n = 1), and neurosurgery (n = 2). There were no Grade III-IV Clavien-Dindo complications. There was one death secondary to ventricular fibrillation in the setting of coronary artery disease. ICI appear safe in the perioperative setting, involving multiple different types of surgery, and likely do not need to be stopped in the perioperative setting. Further studies are warranted to confirm these findings.

KW - Cancer

KW - Immune checkpoint inhibitors

KW - Morbidity

KW - Serious adverse events

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85020874988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020874988&partnerID=8YFLogxK

U2 - 10.3389/fonc.2017.00121

DO - 10.3389/fonc.2017.00121

M3 - Article

AN - SCOPUS:85020874988

VL - 7

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 121

ER -